Benzinga - by Piero Cingari, Benzinga Staff Writer. The S&P 500 Index has risen by 19% year-to-date, with three weeks remaining in the year and just a five percentage point gap...
Benzinga - by Piero Cingari, Benzinga Staff Writer. Investors are always on the lookout for untapped opportunities, especially in stocks that have been heavily discounted and now...
Benzinga - by Benzinga Insights, Benzinga Staff Writer. Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 21.8% on an annualized basis producing an average...
Benzinga - by Benzinga Insights, Benzinga Staff Writer. Moderna's (NYSE:MRNA) short percent of float has risen 14.18% since its last report. The company recently reported that it...
Canaccord initiated shares of Moderna (NASDAQ:MRNA) with a Hold rating and $82 per share price target in a note Wednesday, with analysts stating the company is its own act to...
Benzinga - by Piero Cingari, Benzinga Staff Writer. As holiday shoppers flock to Main Street for Black Friday deals, Wall Street is mirroring this frenzy with its own version of...
Benzinga - by Benzinga Insights, Benzinga Staff Writer. Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 22.22% on an annualized basis producing an...
Hype stock. Trading pharma stocks is tedious at best, in this case, unrewarding too. I wouldn’t bother unless I heard news of a serious covid strain - the kind that sends crude oil down at least 10-15%.
0
What's up with Moderna today?
0
Told ya.
0
Sc mortgage should dump this
0
They have high conviction in this, they believe it offers the best growth story and new drugs in the works.